For US Healthcare Professionals
I am a
Ulcerative Colitis Specialist
FOR ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
What if you could...Have an IL-23i with the choice of both SC or IV induction?1
CD64+ cells are the predominant source of IL-23 in UC. Cells not expressing CD64 may also contribute to IL-23 production, but to a lesser extent.2,4
TREMFYA is the only IL-23i approved for SC dosing for UC from induction through maintenance.1,5,6†
*This is based on information licensed from NPA/DDD with business rules applied and captured only approved induction doses
of IL-23 inhibitors for adults with moderately to severely active Crohn’s disease or ulcerative colitis. Data used to support this
are from 2/21/2026 - 3/27/2026.
CD64=cluster of differentiation 64; DDD=Drug Distribution Data; IL-23=interleukin 23; IL-23i=IL-23 inhibitor;
IV=intravenous; MOA=mechanism of action; NPA=National
Prescription Audit;
SC=subcutaneous.
For illustrative purposes only.
Clinical and endoscopic remission
SC and IV induction
(ASTRO & QUASAR)
(ASTRO & QUASAR)
3-year QUASAR open-label LTE data
Efficacy over time
First SC induction dose in as fast as 1 day‡
Explore TREMFYA withMe
View the established safety profile across pivotal trials
The patient support and resources provided by TREMFYA withMe are not intended to give medical advice, replace a treatment plan from the patient’s healthcare provider, offer services that would normally be performed by the provider’s office, or serve as a reason to prescribe TREMFYA.
†"Only" based on approved selective IL-23 inhibitors for moderately to severely active UC as of June 2026. Compared to Skyrizi® (risankizumab-rzaa) and Omvoh®
(mirikizumab-mrkz) induction and maintenance dosing. Skyrizi® and Omvoh® are not available as SC injection for induction therapy in ulcerative colitis.1,5,6
‡See program requirements for the TREMFYA withMe Trial Offer at TREMFYAwithMeTrial.com.
APP=advanced practice provider; LTE=long-term extension.
When patients were asked to select which device they prefer:
~9out of10
preferred an SC pen
over an on-body injector (OBI) for treatment management7§||
§In a third-party 2025 unbranded market research survey, 506 patients with Crohn's disease or ulcerative colitis were asked to choose which administration method they would prefer for the treatment of disease between an SC injection pen and an SC OBI injection device. It did not evaluate efficacy or safety. While these factors are important, there are additional considerations for selecting treatment.7
||TREMFYA does not offer an SC OBI device.
Recommended Dosing for
Ulcerative Colitis:
- Induction Dose: 400 mg administered by SC injection (given as two consecutive injections of 200 mg each) at Weeks 0, 4, and 8 or
200 mg administered by intravenous infusion over at least one hour at Weeks 0, 4, and 8 - Maintenance Dose: 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter, or 200 mg administered
by subcutaneous injection at Week 12, and every 4 weeks thereafter. Use the lowest effective recommended dosage to maintain
therapeutic response
Pretreatment Evaluations: Evaluate for tuberculosis (TB) infection, evaluate liver enzymes and bilirubin levels, and complete all age-
appropriate vaccinations according to current immunization guidelines.1
Monitor: For signs and symptoms of active TB during and after treatment with TREMFYA; liver enzymes and bilirubin levels for at least 16
weeks of treatment, and periodically thereafter according to routine patient management.1
TREMFYA is intended for use under the guidance and supervision of a healthcare professional. After proper training in subcutaneous
injection technique, adults may self-inject.1
TREMFYA is available as a pen, syringe, and the One-Press patient-controlled injector. Please see instructions for use.
Schedule a meeting with a local representative or an APP specialist
from Johnson & Johnson
References: 1. TREMFYA [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit–specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells. Poster presented at: 18th Congress of the European Crohn’s and Colitis Organisation (ECCO); March 1-4, 2023; Copenhagen, Denmark. Poster P504. 3. Sewell GW, Kaser A. Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention. J Crohns Colitis. 2022;16(suppl 2):ii3-ii19. doi: 10.1093/ecco-jcc/jjac034 4. Krueger JG, Eyerich K, Kuchroo VK, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217. doi: 10.3389/fimmu.2024.1331217 5. Skyrizi® [Prescribing Information]. North Chicago, IL: AbbVie Inc. 2026. 6. Omvoh® [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company. 2025. 7. Data on file. Janssen Biotech, Inc.